Bedrijfsoverzicht
LivaNova PLC is a medical technology firm dedicated to the design, development, manufacturing, and marketing of therapeutic products and services for the cardiovascular sector. The company operates within the healthcare sector, specifically the medical devices industry, which implies a focus on high-precision engineering and regulatory compliance to support critical patient care needs. The organization employs a workforce of 3,300 individuals and maintains a market capitalization of $3.43 billion, reflecting its status as a significant player in the global medical technology landscape. With annual revenue reaching $1.39 billion, the company's financial scale suggests a substantial operational footprint across multiple international markets, including the United States, United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. These valuation and revenue figures collectively indicate that LivaNova PLC possesses the resources to sustain extensive research and development activities while competing in a regulated and capital-intensive industry.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $1.39 billion, accompanied by a net income loss of $242.47 million and an EBITDA of $257.66 million. The substantial gap between the positive EBITDA and the negative net income reveals a significant impact from non-operating expenses, likely driven by the heavy tax and interest costs inherent in the company's international structure. Despite the reported net loss, the entity generated free cash flow of $834.25 million, which provides a strong buffer for financial flexibility and operational resilience. The gross margin stands at 68.0%, indicating a highly profitable cost structure where the majority of revenue is retained after direct production costs. The operating margin is 13.0%, suggesting efficient management of overhead expenses relative to sales volume, whereas the profit margin of -17.5% reflects the bottom-line pressure from non-operating items. On the balance sheet, cash holdings of $635.55 million exceed total debt of $433.77 million, resulting in a debt-to-equity ratio of 36.15 which, while high numerically, is mitigated by the strong cash position. The current ratio of 1.36 indicates that the company holds sufficient current assets to cover its short-term liabilities, pointing to adequate liquidity for meeting immediate obligations. Return on equity is recorded at -19.2%, signaling that the company is currently diluting shareholder value due to losses, while return on assets remains positive at 5.2%, demonstrating that the asset base is generating value before interest and taxes.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the negative net income, while the forward P/E is 13.71, implying that the market prices the stock based on anticipated future earnings rather than current profitability. The price-to-book ratio is 2.86, which suggests that the market values the company at nearly three times its book value, indicating a premium assigned to its intangible assets and growth potential. Alternative valuation metrics such as a price-to-sales ratio of 2.47 and an EV/EBITDA of 12.54 provide context for the company's valuation relative to peers, suggesting a moderate multiple given the high-margin nature of the medical device industry. The stock has traded between a 52-week low of $34.00 and a 52-week high of $71.92, meaning the current price position relative to this range fluctuates based on market sentiment and recent trading activity. With a beta of 0.97, the stock exhibits volatility that closely mirrors the broader market, indicating that price movements are generally in line with general market trends rather than displaying excessive sensitivity to systemic risk.
Growth & Income
Revenue growth year-over-year is 12.1%, while earnings growth year-over-year is -45.6%, indicating that earnings are contracting at a much faster rate than revenue expansion. This divergence suggests that while top-line sales are increasing, the cost structure or non-operating expenses are disproportionately affecting the bottom line, preventing proportional earnings growth. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is retained within the business to fund operations, debt reduction, or reinvestment into new technologies rather than being distributed to shareholders. The overall growth and income profile characterizes LivaNova PLC as a capital-reinvesting growth stock that prioritizes long-term expansion and product development over immediate income generation for investors seeking current yield.